Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Bought by GSA Capital Partners LLP

Key Points

• GSA Capital Partners LLP increased its stake in Arrowhead Pharmaceuticals by 514.4%, acquiring 60,018 additional shares and bringing its total to approximately 71,685 shares worth $913,000.
• Several institutional investors, including Norges Bank and Raymond James Financial Inc., made significant investments in Arrowhead Pharmaceuticals in the fourth quarter, indicating strong institutional interest.
• Analysts have mixed opinions on Arrowhead Pharmaceuticals, with ratings ranging from "strong-buy" to "hold," while the company has a consensus price target of $43.71.

GSA Capital Partners LLP boosted its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 514.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 71,685 shares of the biotechnology company's stock after acquiring an additional 60,018 shares during the quarter. GSA Capital Partners LLP owned 0.05% of Arrowhead Pharmaceuticals worth $913,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Pinnacle Associates Ltd. purchased a new stake in Arrowhead Pharmaceuticals during the 1st quarter worth approximately $1,798,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Arrowhead Pharmaceuticals in the first quarter worth $174,000. Victory Capital Management Inc. increased its position in shares of Arrowhead Pharmaceuticals by 99.2% during the first quarter. Victory Capital Management Inc. now owns 45,283 shares of the biotechnology company's stock worth $577,000 after acquiring an additional 22,546 shares during the period. Edgestream Partners L.P. raised its stake in shares of Arrowhead Pharmaceuticals by 153.7% in the first quarter. Edgestream Partners L.P. now owns 305,507 shares of the biotechnology company's stock valued at $3,892,000 after acquiring an additional 185,096 shares in the last quarter. Finally, CWM LLC increased its holdings in Arrowhead Pharmaceuticals by 134.3% during the 1st quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 2,523 shares during the period. 62.61% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ARWR has been the topic of a number of recent research reports. Wall Street Zen lowered shares of Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Friday, July 18th. TD Cowen upgraded Arrowhead Pharmaceuticals to a "strong-buy" rating in a research note on Monday, July 28th. Citigroup cut their price objective on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. Chardan Capital reaffirmed a "buy" rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 13th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, May 20th. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $43.71.

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR stock traded up $0.01 during mid-day trading on Tuesday, reaching $16.48. The stock had a trading volume of 636,628 shares, compared to its average volume of 1,882,297. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $9.57 and a 12-month high of $27.34. The company has a current ratio of 5.15, a quick ratio of 5.15 and a debt-to-equity ratio of 0.31. The business has a 50-day simple moving average of $16.45 and a 200 day simple moving average of $16.04. The company has a market cap of $2.28 billion, a P/E ratio of -11.76, a price-to-earnings-growth ratio of 18.74 and a beta of 0.94.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The biotechnology company reported $2.75 EPS for the quarter, beating analysts' consensus estimates of ($0.06) by $2.81. The company had revenue of $542.71 million for the quarter, compared to analyst estimates of $116.27 million. During the same period in the previous year, the business earned ($1.02) EPS. On average, sell-side analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.